Abstract:The synaptic vesicle glycoprotein 2C (SV2C) works in concert with the vesicular monoamine transporter 2 (VMAT2) to regulate vesicular dopamine dynamics. Because of the leaky nature of synaptic vesicles, substrate (e.g. FFN206, dopamine, MPP+) will leak out over time, decreasing the vesicular content. Blocking VMAT2 through inhibition results in an increase in the amount of substrate lost over time because of a loss of reuptake capabilities. A lack of SV2C expression similarly results in an increase in the amount of substrate lost over time. The cumulative loss of substrate over time is exacerbated in conditions with no SV2C expression and VMAT2 inhibition. Dopaminergic neurons of the substantia nigra exist in a persistent state of vulnerability resulting from high baseline oxidative stress, high‐energy demand, and broad unmyelinated axonal arborisations. Impairments in the storage of dopamine compound this stress because of cytosolic reactions that transform the vital neurotransmitter into an endogenous neurotoxicant, and this toxicity is thought to contribute to the dopamine neuron degeneration that occurs Parkinson's disease. We have previously identified synaptic vesicle glycoprotein 2C (SV2C) as a modifier of vesicular dopamine function, demonstrating that genetic ablation of SV2C in mice results in decreased dopamine content and evoked dopamine release in the striatum. Here, we adapted a previously published in vitro assay utilising false fluorescent neurotransmitter 206 (FFN206) to visualise how SV2C regulates vesicular dopamine dynamics and determined that SV2C promotes the uptake and retention of FFN206 within vesicles. In addition, we present data indicating that SV2C enhances the retention of dopamine in the vesicular compartment with radiolabelled dopamine in vesicles isolated from immortalised cells and from mouse brain. Further, we demonstrate that SV2C enhances the ability of vesicles to store the neurotoxicant 1‐methyl‐4‐phenylpyridinium (MPP+) and that genetic ablation of SV2C results in enhanced 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced vulnerability in mice. Together, these findings suggest that SV2C functions to enhance vesicular storage of dopamine and neurotoxicants and helps maintain the integrity of dopaminergic neurons.

Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration.

ReducedVesicularStorageofDopamineCausesProgressive NigrostriatalNeurodegeneration

Reduced Vesicular Storage of Dopamine Exacerbates Methamphetamine-Induced Neurodegeneration and Astrogliosis

Alpha Synuclein and Vesicular Monoamine Transporter2 Expression Modulate the Vulnerability of Nigral Neurons to Dopaminergic Neurotoxicants

Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity

Altered striatal dopamine levels in Parkinson’s disease VPS35 D620N mutant transgenic aged mice

Synaptic vesicle glycoprotein 2C enhances vesicular storage of dopamine and counters dopaminergic toxicity

Hvmat2: A Target of Individualized Medication for Parkinson's Disease.

Mutant D620N and VPS35 induces motor dysfunction and impairs DAT-mediated dopamine recycling pathway

Mutant VPS35-D620N Induces Motor Dysfunction and Impairs DAT-mediated Dopamine Recycling Pathway.

Retrograde Trafficking of VMAT2 and Its Role in Protein Stability in Non-Neuronal Cells

VPS35 D620N Knockin Mice Recapitulate Cardinal Features of Parkinson’s Disease

Emergent glutamate & dopamine dysfunction in VPS35(D620N) knock-in mice and rapid reversal by LRRK2 inhibition

The Redistribution of Drosophila Vesicular Monoamine Transporter Mutants from Synaptic Vesicles to Large Dense-Core Vesicles Impairs Amine-Dependent Behaviors

Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration

Striatal dopamine neurotransmission is altered in age- and region-specific manner in a Parkinson's disease transgenic mouse

Dopamine neuron degeneration in the Ventral Tegmental Area causes hippocampal hyperexcitability in experimental Alzheimer's Disease

Progressively disrupted somatodendritic morphology in dopamine neurons in a mouse Parkinson's model

Gain-of-function Haplotypes in the Vesicular Monoamine Transporter Promoter Are Protective for Parkinson Disease in Women

Impaired striatal glutathione–ascorbate metabolism induces transient dopamine increase and motor dysfunction

Neurotransmitter accumulation and Parkinson's disease-like phenotype caused by anion channelrhodopsin opto-controlled astrocytic mitochondrial depolarization in substantia nigra pars compacta